Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Details

Keywords

Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma, Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy

Eligibility

Locations

  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles California 90095 United States
  • University of Alabama at Birmingham Cancer Center
    Birmingham Alabama 35233 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT03107780
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 32 people participating
Last Updated